Last reviewed · How we verify
Xianmin Song, MD — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Akeso · 1 shared drug class
- Bio-Thera Solutions · 1 shared drug class
- Fujian Akeylink Biotechnology Co., Ltd. · 1 shared drug class
- Janssen Research & Development, LLC · 1 shared drug class
- Qilu Pharmaceutical Co., Ltd. · 1 shared drug class
- Shanghai JMT-Bio Inc. · 1 shared drug class
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Xianmin Song, MD:
- Xianmin Song, MD pipeline updates — RSS
- Xianmin Song, MD pipeline updates — Atom
- Xianmin Song, MD pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Xianmin Song, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xianmin-song-md. Accessed 2026-05-16.